35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity 35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity

Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...

SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...